###### Strengths and limitations of this study

-   The strength of this study is the use of a nationwide population-based cohort to identify hearing loss (HL) risk in an Asian population with rheumatoid arthritis (RA). Our findings can be generalised to the general population.

-   The inclusion of the Catastrophic Illness Patient Database confirmed the diagnoses of all RA cases with increased reliability of our data; the large sample size reduced the tendency for selection bias, enhanced statistical power and precision of risk appraisal.

-   Limitations in this study: information on several suspected risk factors for HL, such as smoking and chronic exposure to occupational and environmental noise, which could be associated with HL in the general population, was not available in the insurance database.

-   Information on laboratory test results and HL by severity and sound frequency (high, mid or low frequency) and on RA severity scale, such as disease activity, functional impairment and physical damage, was also unavailable.

Introduction {#s1}
============

Rheumatoid arthritis (RA) is a disease predominantly characterised by chronic joint inflammation and is often accompanied by several peripheral inflammatory manifestations.[@R1] RA may lead to the destruction of the cartilage and bone due to chronic synovitis and may consequently impair joint function.[@R2] In addition, patients with RA may have extra-articular manifestations involving other organ systems,[@R3] such as auditory system alteration, although with a different putative mechanism of damage.[@R4] With respect to the auditory system, previous studies have shown conflicting findings, in both hearing loss (HL) and the RA disease activity and severity.[@R7]

There is a wide variation in the reported prevalence of HL in patients with RA. Sensorineural hearing loss (SNHL) is the most common hearing impairment in patients with RA, ranging from 25% to 72%,[@R11] whereas conductive HL and mixed HL are less frequently reported.[@R4] SNHL could be induced by a direct immune response of either T or B cells against inner ear proteins.[@R13] Neurovascular inflammation and drugs used for RA treatment could also damage the cochlea.[@R14] Thus, HL may be a manifestation of systemic vascular involvement in patients with RA and may have a significant effect on the health of patients with RA. However, the risk of developing HL in patients with RA has not been well examined using population data.

Hence, the purpose of this study was to investigate the risk of HL in patients with RA, using representative insurance claims data obtained from the Taiwan National Health Insurance (NHI). The HL risk associated with other comorbidities, such as coronary heart disease, hypertension, stroke, diabetes, hyperlipidaemia, hyperthyroidism, hypothyroidism, chronic renal disease and autoimmune diseases, was also evaluated.

Materials and methods {#s2}
=====================

Data source {#s2a}
-----------

The Taiwan NHI system is a single-payer compulsory programme with a coverage of over 99% of 23.74 million people.[@R15] We conducted this study using two data sets: the Registry for Catastrophic Illness Patient Database (CIPD) and the Longitudinal Health Insurance Database (LHID2000), obtained from the Taiwan National Health Research Institutes. Patients with major diseases, such as cancer, chronic mental illness, end-stage renal disease and several autoimmune diseases requiring long-term care, are eligible for the CIPD coverage for exemption from making copayment. The LHID2000 contains the claims data of 1 000 000 people randomly sampled from all populations being registered in 2000 for the insurance coverage. Reimbursement claims data for medical services from 1996 to 2011 in both data sets were used in this study. For privacy protection, all personal identifications were replaced with surrogate identifications suitable for public use and data linkage. The claims data contained information on the demographic status of the insured people, dates of treatment and treatments received, diagnostic codes, prescriptions and costs. Diagnoses of diseases were coded with the International Classification of Disease Diagnoses, Ninth Revision of Clinical Modification (ICD-9-CM). Several studies in Taiwan using the insurance claims data have demonstrated high accuracy and validity of ICD-9 diagnosis.[@R16]

Study population {#s2b}
----------------

[Figure 1](#F1){ref-type="fig"} shows the flow chart for identifying and selecting study population using a population-based retrospective cohort study design. We identified an RA cohort from the registry for CIPD and a non-RA cohort from the LHID2000. Patients newly diagnosed with RA (ICD-9-CM 714.0) from 2000 to 2006 without HL were included in the RA cohort. The date with RA certificated as the catastrophic illness was considered as the index date for the approved patients. Patients who met four or more of the diagnostic criteria based on the 1987 American College of Rheumatology criteria were considered as having RA and those diagnosed by rheumatologists were included in the RA cohort.[@R18] The application for catastrophic illness status was scrutinised by peer review.

![Flow chart showing selection of study cohorts. LHID, Longitudinal Health Insurance Database; RA, rheumatoid arthritis.](bmjopen-2017-018134f01){#F1}

For each patient with RA, four insured people without history of RA and HL were randomly selected from the LHID2000 for the non-RA cohort and were frequency matched by sex, age (each 5-year span) and index year. Individuals with missing information on age and/or sex or with history of HL (ICD-9-CM 388.2, 388.4, 389.00, 389.10, 389.12, 389.2 and 389.9) at baseline were excluded from the non-RA cohort.

Both cohorts were followed from the index date to the date with HL diagnosed, death, withdrawal from the NHI system or the end of 2011. In general, HL was diagnosed based on the audiometry test. To increase the validity of HL diagnosis, only patients with three or more diagnoses in outpatient claims or an inpatient record were included in the study. Patients who were suspected of having HL received comprehensive examinations and, subsequently, treatment was followed when the disorder was confirmed. In the insurance system, HL patients' medical reimbursement and discharge notes are scrutinised by peer review. The insurance system also randomly reviewed insurance claims to prevent errors and violations. Therefore, diagnoses and codes of HL in the study were highly reliable.[@R16]

Statistical analysis {#s2c}
--------------------

Distributions of sex and age (20--39, 40--59 and ≥60 years) and baseline comorbidities, including diabetes (ICD-9-CM 250), hyperlipidaemia (ICD-9-CM 272), hypertension (ICD-9-CM 401--405), hyperthyroidism (ICD-9-CM 242), ischaemic heart disease (IHD; ICD-9-CM 410--414), stroke (ICD-9-CM 430--438), chronic kidney disease (CKD; ICD-9-CM 580--589), hypothyroidism (ICD-9-CM 244) and autoimmune diseases (including psoriasis (ICD-9-CM 696), systemic lupus erythematosus (SLE; ICD-9-CM 710.0), systemic sclerosis (ICD-9-CM 710.1), Sjogren syndrome (ICD-9-CM 710.2), dermatomyositis (ICD-9-CM 710.3), polymyositis (ICD-9-CM 710.4) and vasculitis (ICD-9-CM 446.0, 446.2, 446.4, 446.5, 443.1, 446.7, 446.1 and 136.1), between the RA and non-RA cohorts were compared. A standardised mean difference of less than 0.1 was a negligible difference between two means or two prevalence rates.[@R19] The incidence density of HL per 1000 person-years was calculated during the follow-up period by sex, age and comorbidity. The Kaplan-Meier method was employed to plot the cumulative incidence of HL for each cohort during the follow-up period, and the log-rank test was used to assess the differences between the two curves. Univariate and multivariate Cox proportional hazards regression analyses were used to measure the RA cohort to non-RA cohort crude HR (cHR) and adjusted HR (aHR) of HL, respectively, and their 95% CIs. Sex, age and comorbidities including diabetes, hyperlipidaemia, hypertension, hyperthyroidism, hypothyroidism, IHD, stroke, CKD and autoimmune diseases were included as covariates in the multivariate Cox regression analysis. To further assess the robustness of our results, we also evaluated the association between RA and HL risk in various subgroups by sex, age and each comorbidity. We further evaluated the treatment effectiveness of medications for patients with RA by calculating the incidence density and HRs of HL. The HL relating to medications for RA treatment was evaluated, including non-steroidal anti-inflammatory drugs (NSAIDs), prednisolone, disease-modifying antirheumatic drugs (DMARDs, including hydroxychloroquine, sulfasalazine, methotrexate and leflunomide), and tumour necrosis factor (TNF, including etanercept and adalimumab). Further analysis evaluated the HL risk by the type of HL: sensorineural, conductive or mixed.

All analyses were conducted using SAS statistical software (V.9.4 for Windows; SAS Institute), and all statistical tests were performed at the two-tailed significance level of 0.05.

Results {#s3}
=======

We identified 18 267 patients with RA newly diagnosed from 2000 to 2006 for the RA cohort and 73 068 persons without RA for the non-RA cohort as controls ([table 1](#T1){ref-type="table"}). There were more women than men (78.4 vs 21.6%) in both cohorts. Approximately 66.7% of the study populations were \<60 years old. Prevalence rates of CKD and autoimmune diseases were more prevalent in patients with RA than in controls at the baseline.

###### 

Distribution of demographic factors and comorbidity compared between cohorts

  --------------------------------------------------------------------------------------------------------
  Variable                 Non-RA cohort\   RA cohort\   Standardised mean difference            
                           n=73 068         n=18 267                                             
  ------------------------ ---------------- ------------ ------------------------------ -------- ---------
  Sex                                                                                            

   Female                  57 288           78.4         14 322                         78.4     \<0.001

   Male                    15 780           21.6         3945                           21.6     \<0.001

  Age, years                                                                                     

   20--39                  12 224           16.7         3056                           16.7     \<0.001

   40--59                  36 532           50.0         9133                           50.0     \<0.001

   ≥60                     24 312           33.3         6078                           33.3     \<0.001

   Means (SD)              53.3             (14.2)       53.6                           (13.9)   0.021

  Comorbidity                                                                                    

   DM                      8102             11.1         2114                           11.6     0.015

   Hyperlipidaemia         14 078           19.3         3439                           18.8     0.011

   Hypertension            22 844           31.3         5964                           32.7     0.030

   Hyperthyroidism         1089             1.49         456                            2.50     0.072

   IHD                     10 993           15.0         2941                           16.1     0.029

   Stroke                  2128             2.91         483                            2.64     0.016

   CKD                     4821             6.60         2061                           11.3     0.165

   Hypothyroidism          407              0.56         216                            1.18     0.067

   Autoimmune diseases\*   433              0.59         534                            2.92     0.178
  --------------------------------------------------------------------------------------------------------

\*Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis and vasculitis.

CKD, chronic kidney disease; DM, diabetes mellitus; IHD, ischaemic heart disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

The Kaplan-Meier method estimated cumulative incidence of HL was 1.5% greater in the RA cohort than in the non-RA cohort (3.3 vs 1.8%; P value \<0.001 in the log-rank test; [figure 2](#F2){ref-type="fig"}). The incidence density of HL was approximately twofold greater in the RA cohort than in the non-RA cohort (3.08 vs 1.62 per 1000 person-years), with an aHR of 1.91 (95% CI 1.70 to 2.14; [table 2](#T2){ref-type="table"}). Men were at a greater risk of HL than women, and the risk increased with age. Compared with 20--39 years old, the aHRs of HL were 2.89 (95% CI 2.21 to 3.79) and 5.27 (95% CI 3.99 to 6.95) for those aged 40--59 years and those aged ≥60 years, respectively. The HL risk for individuals with comorbidities was also elevated. Patients with hypertension and IHD were significantly associated with higher risk of HL compared with their counterparts without the disorder, with aHRs of 1.21 (95% CI 1.07 to 1.38) and of 1.36 (95% CI 1.19 to 1.56), respectively.

![Kaplan-Meier method estimated cumulative incidence curves of hearing loss in the two cohorts. RA, rheumatoid arthritis.](bmjopen-2017-018134f02){#F2}

###### 

Cox model measured HRs and 95% CIs of hearing loss associated with RA and covariates

  -------------------------------------------------------------------------------------------------------------------------------
  Variable               Event (n)   Person-years   Incidence density†          \                    
                                                                                HR (95% CI)          
  ---------------------- ----------- -------------- -------------------- --------------------------- ----------------------------
  RA                                                                                                 

   No                    927         572 031        1.62                 Ref                         Ref

   Yes                   429         139 085        3.08                 1.90 (1.70 to 2.13)\*\*\*   1.91 (1.70 to 2.14) \*\*\*

  Sex                                                                                                

   Female                977         565 205        1.73                 Ref                         Ref

   Male                  379         145 912        2.60                 1.49 (1.33 to 1.68)\*\*\*   1.40 (1.24 to 1.58)\*\*\*

  Age, years                                                                                         

   20 -- 39              59          123 836        0.48                 Ref                         Ref

   40 -- 59              563         368 175        1.53                 3.21 (2.45 to 4.19)\*\*\*   2.89 (2.21 to 3.79)\*\*\*

   ≥ 60                  734         219 105        3.35                 6.98 (5.35 to 9.10)\*\*\*   5.27 (3.99 to 6.95)\*\*\*

  **Comorbidity**                                                                                    

  DM                                                                                                 

   No                    1127        638 984        1.76                 Ref                         Ref

   Yes                   229         72 133         3.17                 1.78 (1.55 to 2.06)\*\*\*   1.14 (0.98 to 1.33)

  Hyperlipidaemia                                                                                    

   No                    974         578 643        1.68                 Ref                         Ref

   Yes                   382         132 474        2.88                 1.70 (1.51 to 1.92)\*\*\*   1.10 (0.97 to 1.26)

  Hypertension                                                                                       

   No                    714         499 747        1.43                 Ref                         Ref

   Yes                   642         211 370        3.04                 2.11 (1.90 to 2.35)\*\*\*   1.21 (1.07 to 1.38)\*

  Hyperthyroidism                                                                                    

   No                    1325        699 624        1.89                 Ref                         Ref

   Yes                   31          11 492         2.70                 1.41 (0.99 to 2.02)         1.33 (0.92 to 1.92)

  IHD                                                                                                

   No                    987         610 475        1.62                 Ref                         Ref

   Yes                   369         100 642        3.67                 2.25 (2.00 to 2.54)\*\*\*   1.36 (1.19 to 1.56)\*\*\*

  Stroke                                                                                             

   No                    1310        695 656        1.88                 Ref                         Ref

   Yes                   46          15 461         2.98                 1.55 (1.15 to 2.07)\*\*     0.85 (0.63 to 1.14)

  CKD                                                                                                

   No                    1204        662 599        1.82                 Ref                         Ref

   Yes                   152         48 517         3.13                 1.71 (1.45 to 2.03)\*\*\*   1.06 (0.89 to 1.26)

  Hypothyroidism                                                                                     

   No                    1343        706 448        1.90                 Ref                         Ref

   Yes                   13          4668           2.78                 1.46 (0.85 to 2.52)         1.15 (0.65 to 2.01)

  Autoimmune diseases§                                                                               

   No                    1334        704 142        1.89                 Ref                         Ref

   Yes                   22          6975           3.15                 1.65 (1.08 to 2.51)\*       1.34 (0.88 to 2.05)
  -------------------------------------------------------------------------------------------------------------------------------

\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.

†Per 1000 person-years.

‡Multivariate Cox proportional hazards regression model, including RA, sex, age (categorical), DM, hyperlipidaemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism and autoimmune diseases.

§Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis and vasculitis.

CKD, chronic kidney disease; DM, diabetes mellitus; IHD, ischaemic heart disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

[Table 3](#T3){ref-type="table"} shows that incidence rates of HL stratified by sex, age and comorbidity were consistently greater in the RA cohort than in the non-RA cohort. Comorbidity was associated with further increased HL risk for patients with RA. Patients with RA with comorbid IHD had the highest incident HL, 5.60 per 1000 person-years.

###### 

Incidence density and RA cohort to non-RA cohort HRs of hearing loss by sex, age and comorbidity in the two cohorts

  Variables               Non-RA cohort   RA cohort   RA cohort to non-RA cohort                                                      
  ----------------------- --------------- ----------- ---------------------------- ----- --------- ------ --------------------------- ---------------------------
  Sex                                                                                                                                 
   Women                  663             454 249     1.46                         314   110 956   2.83   1.94 (1.69 to 2.22)\*\*\*   1.95 (1.70 to 2.23)\*\*\*
   Men                    264             117 782     2.24                         115   28 130    4.09   1.82 (1.46 to 2.27)\*\*\*   1.85 (1.48 to 2.30)\*\*\*
  Age, years                                                                                                                          
   20--39                 40              98 817      0.40                         19    25 020    0.76   1.89 (1.09 to 3.26)\*       1.80 (1.02 to 3.16)\*
   40--59                 355             295 193     1.20                         208   72 982    2.85   2.37 (2.00 to 2.81)\*\*\*   2.32 (1.95 to 2.76)\*\*\*
   ≥60                    532             178 021     2.99                         202   41 084    4.92   1.63 (1.39 to 1.92)\*\*\*   1.62 (1.37 to 1.90)\*\*\*
  Comorbidity                                                                                                                         
   DM                                                                                                                                 
    No                    765             514 262     1.49                         362   124 722   2.90   1.95 (1.72 to 2.21)\*\*\*   1.94 (1.71 to 2.20)\*\*\*
    Yes                   162             57 770      2.80                         67    14 363    4.66   1.66 (1.25 to 2.21)\*\*\*   1.74 (1.30 to 2.32)\*\*\*
   Hyperlipidaemia                                                                                                                    
    No                    654             464 753     1.41                         320   113 890   2.81   2.00 (1.75 to 2.28)\*\*\*   1.96 (1.72 to 2.25)\*\*\*
    Yes                   273             107 279     2.54                         109   25 195    4.33   1.69 (1.36 to 2.11)\*\*\*   1.74 (1.39 to 2.18)\*\*\*
   Hypertension                                                                                                                       
    No                    481             402 716     1.19                         233   97 031    2.40   2.01 (1.72 to 2.35)\*\*\*   1.94 (1.66 to 2.28)\*\*\*
    Yes                   446             169 316     2.63                         196   42 054    4.66   1.76 (1.49 to 2.08)\*\*\*   1.82 (1.54 to 2.16)\*\*\*
   Hyperthyroidism                                                                                                                    
    No                    909             563 891     1.61                         416   135 733   3.06   1.90 (1.69 to 2.13)\*\*\*   1.92 (1.71 to 2.16)\*\*\*
    Yes                   18              8140        2.21                         13    3352      3.88   1.76 (0.86 to 3.58)         1.72 (0.84 to 3.55)
   IHD                                                                                                                                
    No                    671             491 566     1.37                         316   118 909   2.66   1.95 (1.70 to 2.23)\*\*\*   1.96 (1.71 to 2.24)\*\*\*
    Yes                   256             80 466      3.18                         113   20 176    5.60   1.75 (1.40 to 2.18)\*\*\*   1.75 (1.40 to 2.19)\*\*\*
   Stroke                                                                                                                             
    No                    896             559 458     1.60                         414   136 197   3.04   1.90 (1.69 to 2.13)\*\*\*   1.90 (1.69 to 2.14)\*\*\*
    Yes                   31              12 573      2.47                         15    2888      5.19   2.10 (1.13 to 3.89)\*       2.18 (1.16 to 4.12)\*
   CKD                                                                                                                                
    No                    835             538 065     1.55                         369   124 534   2.96   1.91 (1.69 to 2.16)\*\*\*   1.94 (1.71 to 2.19)\*\*\*
    Yes                   92              33 967      2.71                         60    14 551    4.12   1.53 (1.11 to 2.12)\*       1.73 (1.25 to 2.42)\*\*
   Hypothyroidism                                                                                                                     
    No                    917             569 055     1.61                         426   137 393   3.10   1.92 (1.71 to 2.16)\*\*\*   1.94 (1.73 to 2.18)\*\*\*
    Yes                   10              2977        3.36                         3     1692      1.77   0.53 (0.15 to 1.93)         0.69 (0.19 to 2.57)
   Autoimmune diseases§                                                                                                               
    No                    916             568 956     1.61                         418   135 186   3.09   1.92 (1.71 to 2.15)\*\*\*   1.94 (1.73 to 2.18)\*\*\*
    Yes                   11              3076        3.58                         11    3899      2.82   0.79 (0.34 to 1.82)         0.89 (0.38 to 2.07)

\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.

†Per 1000 person-years.

‡Model mutually adjusted for sex, age (continuous), DM, hyperlipidaemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism and autoimmune diseases.

§Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis and vasculitis.

CKD, chronic kidney disease; DM, diabetes mellitus; IHD, ischaemic heart disease; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

[Table 4](#T4){ref-type="table"} shows that medications were associated with reduced incident HL for patients with RA. Near 99% of patients with RA used NSAIDs, and users had an HL incidence of 2.98 per 1000 person-years, with an aHR of 0.12 (95% CI 0.07 to 0.20) compared with non-users who had an incidence of 30.1 per 1000 person-years for HL. Patients with RA on medications of adalimumab (n=950) had the lowest HL incidence of 0.64 per 1000 person-years with an aHR of 0.23 (95% CI 0.10 to 0.55), compared with non-users who had an incidence of 3.23 per 1000 person-years.

###### 

Incidence density and HRs of hearing loss associated with medication in patients with RA

  Medicine use          N        Event (n)   Person-years   Incidence density†   HR (95% CI)                 
  --------------------- -------- ----------- -------------- -------------------- --------------------------- ---------------------------
  NSAIDs                                                                                                     
   No                   169      16          532            30.1                 Ref                         Ref
   Yes                  18 098   413         138 553        2.98                 0.11 (0.07 to 0.18)\*\*\*   0.12 (0.07 to 0.20)\*\*\*
  Prednisolone                                                                                               
   No                   1673     60          11 529         5.20                 Ref                         Ref
   Yes                  16 594   369         127 556        2.89                 0.56 (0.43 to 0.74)\*\*\*   0.53 (0.40 to 0.70)\*\*\*
  DMARDs                                                                                                     
   Hydroxychloroquine                                                                                        
    No                  12 200   309         91 284         3.39                 Ref                         Ref
    Yes                 6067     120         47 801         2.51                 0.75 (0.60 to 0.92)\*\*     0.77 (0.62 to 0.95)\*
   Sulfasalazine                                                                                             
    No                  5141     148         36 176         4.09                 Ref                         Ref
    Yes                 13 126   281         102 909        2.73                 0.68 (0.56 to 0.83)\*\*\*   0.74 (0.61 to 0.91)\*\*
   Methotrexate                                                                                              
    No                  9261     268         67 188         3.99                 Ref                         Ref
    Yes                 9006     161         71 897         2.24                 0.57 (0.47 to 0.69)\*\*\*   0.65 (0.53 to 0.79)\*\*\*
   Leflunomide                                                                                               
    No                  15 393   405         116 118        3.49                 Ref                         Ref
    Yes                 2874     24          22 967         1.04                 0.30 (0.20 to 0.45)\*\*\*   0.33 (0.22 to 0.50)\*\*\*
  TNF                                                                                                        
   Etanercept                                                                                                
    No                  16 259   408         122 506        3.33                 Ref                         Ref
    Yes                 2008     21          16 579         1.27                 0.39 (0.25 to 0.60)\*\*\*   0.44 (0.28 to 0.68)\*\*\*
   Adalimumab                                                                                                
    No                  17 317   424         131 303        3.23                 Ref                         Ref
    Yes                 950      5           7783           0.64                 0.20 (0.08 to 0.48)\*\*\*   0.23 (0.10 to 0.55)\*\*

\*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001.

†Per 1000 person-years.

‡Model adjusted for sex, age, DM, hyperlipidaemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism and autoimmune diseases.

CKD, chronic kidney disease; DM, diabetes mellitus; DMARD, disease-modifying antirheumatic drug; IHD, ischaemic heart disease; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; TNF, tumour necrosis factor.

Further evaluation on the subtype HL showed that patients with RA had only few cases of conductive HL, but were at increased risk of sensorineural HL and mixed HL with aHRs of 2.35 (95% CI 1.91 to 2.89) and 1.77 (95% CI 1.54 to 2.03), respectively ([table 5](#T5){ref-type="table"}).

###### 

Incidence density and HRs for subtypes of HL according to RA status

  Types of HL     RA    Compared with non-RA group                                            
  --------------- ----- ---------------------------- ----- ------ --------------------------- ---------------------------
  Sensorineural   249   0.44                         144   1.04   2.38 (1.94 to 2.92)\*\*\*   2.35 (1.91 to 2.89)\*\*\*
  Conductive      10    0.02                         1     0.01   0.41 (0.05 to 3.21)         0.41 (0.05 to 3.23)
  Mixed           668   1.17                         284   2.04   1.75 (1.52 to 2.01)\*\*\*   1.77 (1.54 to 2.03)\*\*\*

ICD-9-CM: sensorineural, 389.10 and 389.12; conductive, 389.00; mixed, 388.2, 388.4, 389.2 and 389.9.

\*Per 1000 person-years.

†Model adjusted for sex, age (continuous), DM, hyperlipidaemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism and autoimmune diseases.

\*\*\*P\<0.001.

CKD, chronic kidney disease; DM, diabetes mellitus; HL, hearing loss; ICD-9-CM, International Classification of Disease Diagnoses, Ninth Revision of Clinical Modification; IHD, ischaemic heart disease; RA, rheumatoid arthritis.

Discussion {#s4}
==========

This retrospective cohort study showed that patients with RA were nearly twofold more likely to develop HL than those without RA. The risk of HL associated with RA increased with age. In the RA cohort, those ≥60 years old had an HL incidence of 4.92 per 1000 person-years, which was 4.16 per 1000 person-year greater than that of patients aged 20--39 years. The corresponding difference was 2.49 per 1000 person-years between the two age groups in the non-RA cohort, reflecting the natural HL by ageing in the non-RA cohort. Similar to reports in other studies, HL is age dependent in patients and control subjects.[@R6] This finding is also consistent with previous studies for patients with sudden SNHL comorbid with SLE and psoriasis.[@R21] The excess HL risk could be 50% in patients with psoriasis.

We also found that, in the RA cohort, men had an incidence of 4.09 per 1000 person-years for HL, which was 1.26 per 1000 person-years greater than women had. The corresponding difference was 0.78 per 1000 person-years in the non-RA cohort, indicating that the relationship between RA and HL risk may be slightly greater for men. In the entire study population, the overall aHR was 1.40 for men compared with women ([table 2](#T2){ref-type="table"}). There is a remarkable imbalance between the number of males and females with autoimmune diseases, with females representing the majority of cases. Although reasons for this over-representation of women are unclear, genetic (X-linked) factors and hormonal aspects are likely involved. Halligan *et al*[@R23] investigated patients with RA and also demonstrated that the prevalence of abnormal hearing is significantly greater in males (86% or 12/14) than in females (33% or 5/15) (P=0.008). However, no significant gender difference in HL among those without RA was found (P=0.715).

Evidences have shown that patients with RA are prevalent with comorbidities, such as IHD,[@R24] stroke,[@R27] hypertension,[@R28] diabetes,[@R30] dyslipidaemia,[@R27] CKD[@R34] and thyroid disorders.[@R36] In this study, the study populations in both cohorts were young. The baseline prevalence rates of most comorbidities between the two cohorts were not significantly different, except that CKD and autoimmune diseases were more prevalent in patients with RA than in controls without RA at the baseline ([table 1](#T1){ref-type="table"}). However, it is interesting to note that most of the comorbidities are associated with further increased incidence of HL, greater for the RA cohort than for the non-RA cohort, except hypothyroidism, and autoimmune diseases ([table 3](#T3){ref-type="table"}). Autoimmune disease is a possible pathology associated with SNHL because of the destruction of the cochlear hair cells.[@R39] Our study failed to prove this relationship.

The development of RA and the breakdown of atherosclerotic plaques possibly share common factors contributing to inflammatory cells and proinflammatory cytokines.[@R25] Proinflammatory cytokines may contribute to the oxidative damage in the inner ear.[@R26] For example, both TNF-α and interleukin (IL)-6 are involved in the pathogenesis of both RA and atherosclerosis.[@R40] However, Takatsu *et al* showed that the proinflammatory cytokines (IL-6) and matrix matalloproteinase-3 may contribute to harm in inner ear cells by an oxidative process.[@R6] Both RA and HL may have a shared mechanism associating with cardiovascular diseases which account for the higher risk of HL in patients with RA. IHD alone may associate with HL. An earlier study found that patients with IHD are prevalent with HL for up to over 30%.[@R41] Moreover, in this study, we found that patients with RA with IHD had the highest HL incidence among patients with cardiovascular disorders. Hence, RA and cardiovascular disorders may have a shared contribution to the HL risk.

Furthermore, several studies have reported elevated plasma renin and ACE activities in patients with RA.[@R42] Poor blood pressure control could induce changes in the renin--angiotensin system. Higher oxidative stress in patients with RA could also impair the vasodilatory mechanism of the endothelium,[@R43] which could be associated with the higher HL risk in patients with RA. Hence, hypertension is likely another risk factor contributing to HL. The findings in our study further demonstrate the association between autoimmune disease and HL risk.

After adjustment for sex, age and comorbidity, we found reduced HL risk for patients with RA on medication of NSAID, prednisolone, DMARDs and TNF. Conversely, Halligan *et al*[@R23] described an association between HL and hydroxychloroquine, and Dikici *et al*[@R44] observed a dose relation between HL using methotrexate. On the other hand, some studies found no relationship between HL and RA treatment using NSAID, corticosteroid and DMARDs.[@R6] The inconsistent results may be due to the relatively small study sample sizes, whereas our study is a nationwide population-based cohort with large sample size. It is likely that the reduced inflammation in patients with RA on medications of NSAID, corticosteroid, DMARDs and TNF could be associated with reducing the HL risk.

The strength of this study is the use of a nationwide population-based cohort to evaluate HL risk in an Asian population with RA. Our findings can be generalised to the general population. The large sample size allowed the identification of risk factors associated with the development of HL in Taiwan with a minimal tendency for selection bias and enhanced the statistical power and precision of risk appraisal. In addition, the inclusion of the CIPD confirmed the diagnoses of all RA cases in the NHIRD database, which increased the reliability of our data.

However, several limitations to the interpretation of our findings should be considered. Information on several suspected risk factors for HL was unavailable, such as smoking and chronic exposure to occupational and environmental noise, which could be associated with HL for both cohorts. Moreover, information was also unavailable on laboratory test results, HL severity and RA severity scale and activity, functional impairment and physical damage of the disease. Hearing impairments by specific sound frequency were not measured to differentiate high, mid or low frequency HL.

In conclusion, this study demonstrated that patients with RA are at an elevated risk of developing HL. Our findings also suggest the need for prompt treatment and early detection of RA for HL prevention. Appropriate and timely medical interventions may improve the prognosis of HL for patients diagnosed with RA.
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